Cibus (CBUS) announced that it has successfully completed edits in Canola for its 4th mode of action for its Sclerotinia resistance trait and expects greenhouse results in the first quarter of 2025. Multiple modes of action, which are akin to a plant’s defenses to disease, are critical for durable disease resistance. This advancement builds upon the Company’s previously announced field trial results for its 2nd mode of action showing enhanced resistance to Sclerotinia in Canola plants edited with Cibus’ Sclerotinia resistance trait.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBUS:
- Cibus Reports Strategic Shift and Financial Update
- Cibus reports Q3 EPS ($7.63) vs. ($1.59 ) last year
- Cibus announces next generation edits for HT2 in Canola show tolerance
- Cibus Advances in Agricultural Biotechnology Innovations
- Cibus announces restructuring including reduction in force
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
